Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Pleural Effusion, Malignant 6Neoplasm Metastasis 4Solitary Fibrous Tumor, Pleural 1Mesothelioma, Malignant 1Mesothelioma 1Lung Diseases 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Pemetrexed 39Cisplatin 33pembrolizumab 21Nivolumab 17Carboplatin 16Ipilimumab 13Gemcitabine 10Cyclophosphamide 9fludarabine 6durvalumab 6Bevacizumab 6Radiotherapy, Intensity-Modulated 4LMB-100 4Dexamethasone 4tremelimumab 3tazemetostat 3spartalizumab 3olaparib 3niraparib 3atezolizumab 3anetumab ravtansine 3amatuximab 3Vinorelbine 3Paclitaxel 3Imatinib Mesylate 3Cerebral Decortication 3tislelizumab 2sargramostim 2fludarabine phosphate 2defactinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Mesothelioma × Talc × Clear all
NCT02511600 2015-12-15

Comparison of Progel Sealant to Standard of Care (SOC) for Patients Undergoing Decortication

M.D. Anderson Cancer Center

Phase 3 Withdrawn
Other solid neoplasmThoracic

Lung Diseases, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡